If you live and work in an urban area, you might think about the air quality outside your home or workplace. But what about the air quality inside the office? It turns out that on average, indoor environments have higher concentrations of potentially harmful substances, such as aerosols and volatile organic compounds (VOCs). While past research has focused on chemical emissions from building materials, cleaning supplies, and even furniture, air pollution researchers are increasingly looking at another source of toxic air: us.
New research from Purdue University to be presented at the American Association for Aerosol Research conference has found that the majority of indoor VOCs may be released by a seemingly innocuous source: human beings, their lunches and coffee breaks, and anything they may wear or bring to work. And many of these compounds, such as the terpenes released by peeling an orange, or the squalene released in human skin oil, react with ozone to form even more worrisome molecules.
If you’ve ever played the classic puzzle-like computer game Tetris, you know that it starts out slowly. As the seven different pieces (called “zoids” by the initiated) descend from the top of the screen, a player has to shift the pieces horizontally and rotate them so that they fit into a gap in the stack of pieces at the bottom of the screen, or “well.” In early levels, the pieces might take 10-15 seconds to fall. The speed increases at each level.
In world champion Tetris matches, players often start play at Level 18—in which pieces are on the screen for about a second. Wayne Gray, a professor of cognitive science at Rensselaer Polytechnic University, calls it a problem of “predictive processing and predictive action.” Champion-level expert players, he says, are able to take in the state of the gameboard and react almost immediately, without going through the mental steps of figuring out how to move the piece and rotate it that a novice player requires. “They can see the problem and reach a decision at the same time,” he said.
The pharmaceutical industry has been on a 30 year mission to develop a drug to treat Alzheimer’s disease. The culprits behind the disease, they thought, were the amyloid plaques that build up in the brains of these patients. For many decades removing these plaques to treat Alzheimer’s was the goal.
But then drug after drug targeting amyloid failed to improve the symptoms of Alzheimer’s—the so-called “amyloid hypothesis” wasn’t bearing out. But drug companies kept developing and testing drugs that attacked amyloid from every angle—perhaps at the expense of pursuing other avenues of treatment.
This past summer, two more high profile clinical trials of drugs to treat Alzheimer’s failed. That brings the number of successful treatments for the disease, which affects 5.8 million Americans, to zero.
Podden och tillhörande omslagsbild på den här sidan tillhör Science Friday and WNYC Studios. Innehållet i podden är skapat av Science Friday and WNYC Studios och inte av, eller tillsammans med, Poddtoppen.